Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07403552 · ClinicalTrials.gov registry record · Phase 1

Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

A Phase 1 study of Healthy, sponsored by Ensho Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT07403552 is a Phase 1 study of Healthy that is actively recruiting participants, run by Ensho Therapeutics. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07403552, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Ensho Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.

Conditions Studied

Interventions

  • DRUG NSHO-101

Study Locations (1)

California

  • Cenexel Anaheim CA - Anaheim

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2026-01-31
Est. Completion 2026-06
Phase Phase 1

Sponsor

Ensho Therapeutics

1 total trials

What the Registry Record Tells You About NCT07403552

The ClinicalTrials.gov registry entry for NCT07403552 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Ensho Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which NSHO-101 is the first listed.

NCT07403552 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07403552 about?

NCT07403552 is a clinical study titled "Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants". The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.

What is the current status of trial NCT07403552?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-01-31. Estimated completion is 2026-06.

What conditions does trial NCT07403552 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT07403552?

The interventions under investigation include: NSHO-101 (DRUG).

Who is sponsoring clinical trial NCT07403552?

This trial is sponsored by Ensho Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07403552 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.